Literature DB >> 2576466

Pharmacokinetics in pregnancy and placental drug transfer.

F Reynolds, C Knott.   

Abstract

Total body water increases in pregnancy and while the uterus, placenta, fetus, and amniotic fluid constitute part of this increase, the largest component is in the extracellular water. Fat stores also increase and thus the distribution volumes of all drugs expand, but the major effect is seen in polar drugs which are confined to the extracellular space. Cardiac output and renal function also increase and elimination of polar drugs is accelerated. In contrast, the elimination of lipophilic drugs may be retarded, and the effect on intermediate drugs is variable. Polar drugs cross the placenta slowly and accumulate in amniotic fluid and therefore in the fetal gut lumen. Lipophilic drugs cross the placenta rapidly and their transplacental distribution is dependent on relative maternal and fetal affinity: this is determined largely by protein binding on either side of the placenta. The fetus and neonate dispose of all drugs less rapidly than adults, the most efficient elimination processes being sulphate conjugation and renal excretion.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2576466

Source DB:  PubMed          Journal:  Oxf Rev Reprod Biol


  14 in total

1.  The pharmacokinetics of mecillinam and pivmecillinam in pregnant and non-pregnant women.

Authors:  A Heikkilä; K Pyykkö; R Erkkola; E Iisalo
Journal:  Br J Clin Pharmacol       Date:  1992-06       Impact factor: 4.335

Review 2.  Therapeutic drug monitoring in pregnancy: rationale and current status.

Authors:  C Knott; F Reynolds
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of neuromuscular relaxants in pregnancy.

Authors:  J Guay; Y Grenier; F Varin
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

4.  Preliminary buprenorphine sublingual tablet pharmacokinetic data in plasma, oral fluid, and sweat during treatment of opioid-dependent pregnant women.

Authors:  Marta Concheiro; Hendreé E Jones; Rolley E Johnson; Robin Choo; Marilyn A Huestis
Journal:  Ther Drug Monit       Date:  2011-10       Impact factor: 3.681

Review 5.  Pharmacokinetic optimisation of general anaesthesia in pregnancy.

Authors:  T Gin
Journal:  Clin Pharmacokinet       Date:  1993-07       Impact factor: 6.447

Review 6.  Effects of antihypertensive drugs on the unborn child: what is known, and how should this influence prescribing?

Authors:  S M Khedun; B Maharaj; J Moodley
Journal:  Paediatr Drugs       Date:  2000 Nov-Dec       Impact factor: 3.022

7.  Effects of in vivo heregulin beta1 treatment in wild-type and ErbB gene-targeted mice depend on receptor levels and pregnancy.

Authors:  S O'Shea; K Johnson; R Clark; M X Sliwkowski; S L Erickson
Journal:  Am J Pathol       Date:  2001-05       Impact factor: 4.307

Review 8.  Drug transfer and metabolism by the human placenta.

Authors:  Michael R Syme; James W Paxton; Jeffrey A Keelan
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

9.  Pharmacokinetics and transplacental passage of imipenem during pregnancy.

Authors:  A Heikkilä; O V Renkonen; R Erkkola
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

Review 10.  Models for placental transfer studies of drugs.

Authors:  P Bourget; C Roulot; H Fernandez
Journal:  Clin Pharmacokinet       Date:  1995-02       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.